Have A Question?
Contact us
UK Ireland
T: 44 (0) 1707 37 22 11
E:info@analytiqa.com
T: 353 (0) 16 40 18 18
E:info@analytiqa.com
#

Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results 03 February 2016

Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3%

Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7% Negative Impact from Foreign Exchange and 3% Net Favourable Impact from Acquisitions and Divestitures

Full-Year 2015 Worldwide Sales Were $39.5 Billion, a Decrease of 6%, Reflecting a 6% Negative Impact from Foreign Exchange and a 3% Net Unfavourable Impact from Acquisitions and Divestitures

2016 Financial Outlook:

Expects Full-Year 2016 GAAP EPS to be Between $1.96 and $2.23; Expects Non-GAAP EPS to be Between $3.60 and $3.75, Including an Approximately 4 Percent Negative Impact from Foreign Exchange

Anticipates Full-Year 2016 Worldwide Sales to be Between $38.7 Billion and $40.2 Billion, Including an Approximately 3 Percent Negative Impact from Foreign Exchange

Advanced KEYTRUDA Program

sBLA Approval for Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1

Expanded Indication for First-Line Treatment of Patients with Unresectable or Metastatic Melanoma

Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C